Science Explorer Back to mapMap
Discussion
Topic · Oncology

Peptidase Inhibition and Analysis

Peptidase Inhibition and Analysis is a research topic within Oncology. Science Explorer counts 57k research works in it since 1950. 10.1% of them reached the world's top 10% most cited for their field and year.

This cluster of papers explores the role of fibroblast activation in cancer progression, focusing on the expression of fibroblast activation protein, immunosuppression in the tumor microenvironment, N-terminal acetylation of proteins, protease inhibitors for cancer therapy, angiogenesis, and PET imaging to target stromal cells in the tumor microenvironment.

  • Fibroblast Activation Protein
  • Tumor Microenvironment
  • Immunosuppression
  • Cancer Therapy
  • N-terminal Acetylation
  • Protease Inhibitors
  • Angiogenesis
  • PET Imaging
  • Stromal Cells
  • Tumor Stroma
Research works
57k
fractional, since 1950
In the world top 10%
5.7k
per year above
Top-10% rate
10.1%
share of its works in the world top 10%
Growth, 2018-21 → 2022-25
+22%
the tick is no change
Largest producer
China
40% of the 10 largest, 2022-now
Peptidase Inhibition and Analysis

This ranks research output and citation impact. It says nothing about the quality of diagnosis, treatment or care.

Which countries lead Peptidase Inhibition and Analysis research?

By volume, China and the United States publish the most (3.2k and 2.1k works in 2022-now).

By volume, 2022-now

  1. 1 China 3.2k works
  2. 2 United States 2.1k works
  3. 3 Germany 531 works
  4. 4 India 500 works
  5. 5 Japan 443 works
  6. 6 United Kingdom 327 works
  7. 7 Italy 307 works
  8. 8 France 236 works
  9. 9 South Korea 223 works
  10. 10 Spain 204 works

How concentrated that is

The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.

China: 39.9%United States: 25.8%Germany: 6.6%India: 6.2%6 others listed: 21.5%40%largest
China3,228 · 39.9%United States2,091 · 25.8%Germany531 · 6.6%India500 · 6.2%6 others listed1,740 · 21.5%

Shares of the rows listed above, not of the whole node.

Which institutions lead Peptidase Inhibition and Analysis research?

By volume in 2022-now, Harvard University publishes the most Peptidase Inhibition and Analysis research, followed by Sun Yat-sen University and Shanghai Jiao Tong University.

By volume, 2022-now

  1. 1 Harvard UniversityUnited States 103 works
  2. 2 Sun Yat-sen UniversityChina 99 works
  3. 3 Shanghai Jiao Tong UniversityChina 92 works
  4. 4 Chinese Academy of SciencesChina 90 works
  5. 5 Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina 79 works
  6. 6 Peking UniversityChina 79 works
  7. 7 Sichuan UniversityChina 77 works
  8. 8 Zhejiang UniversityChina 61 works
  9. 9 Nanjing Medical UniversityChina 58 works
  10. 10 Fudan UniversityChina 56 works

Who are the leading researchers in Peptidase Inhibition and Analysis?

The most-cited researchers publishing on Peptidase Inhibition and Analysis include Mark J. Daly, Stacey L. Gabriel and Peer Bork.

  1. 1 Mark J. Daly United States 403k citations
  2. 2 Stacey L. Gabriel United States 402k citations
  3. 3 Peer Bork Germany 396k citations
  4. 4 Guido Kroemer France 386k citations
  5. 5 Bert Vogelstein United States 373k citations
  6. 6 Gad A. Getz United States 364k citations
  7. 7 John J.V. McMurray United Kingdom 349k citations
  8. 8 Elaine R. Mardis United States 346k citations
  9. 9 Hermann Brenner Germany 343k citations
  10. 10 Emelia J. Benjamin United States 341k citations

Ranked by citations received across their whole record, among researchers with at least three works on this topic.

What are the most cited papers in Peptidase Inhibition and Analysis?

The most cited paper in Peptidase Inhibition and Analysis is "Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene" (Dennis J. Slamon, Gary M. Clark, Steven Wong et al., 1987), with 11,844 citations. Next come "Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer" (10,303) and "Peptidotriazoles on Solid Phase: [1,2,3]-Triazoles by Regiospecific Copper(I)-Catalyzed 1,3-Dipolar Cycloadditions of Terminal Alkynes to Azides" (8,627).

Most cited papers
#PaperReleasedCitations
1 Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene Dennis J. Slamon, Gary M. Clark, Steven Wong et al. · Science 9 Jan 1987 11,844
2 Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer Martin Reck, Delvys Rodríguez‐Abreu, Andrew George Robinson et al. · New England Journal of Medicine Open access 9 Oct 2016 10,303
3 Peptidotriazoles on Solid Phase: [1,2,3]-Triazoles by Regiospecific Copper(I)-Catalyzed 1,3-Dipolar Cycloadditions of Terminal Alkynes to Azides Christian Wenzel Tornøe, Caspar Elo Christensen, Morten Meldal · The Journal of Organic Chemistry 2 Apr 2002 8,627
4 In situ click chemistry generation of cyclooxygenase-2 inhibitors Atul Bhardwaj, Jatinder Paul Kaur, Melinda Wuest et al. · Nature Communications Open access 9 Feb 2017 7,563
5 Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial Yung‐Jue Bang, Eric Van Cutsem, Andrea Feyereislova et al. · The Lancet Open access Aug 2010 7,405
All 100 most cited papers, with filters and sorting

Where is Peptidase Inhibition and Analysis research done?

The largest centres of Peptidase Inhibition and Analysis research in 2022-now are Beijing (China), Shanghai (China), Guangzhou (China) and Nanjing (China). Among places with at least 20 works in it, it is an unusually large share of all research in Luzhou.

Largest cities, 2022-now

  1. 1 BeijingChina 419 works
  2. 2 ShanghaiChina 317 works
  3. 3 GuangzhouChina 237 works
  4. 4 NanjingChina 146 works
  5. 5 HangzhouChina 131 works
  6. 6 WuhanChina 127 works
  7. 7 TokyoJapan 117 works
  8. 8 ChengduChina 115 works
  9. 9 SeoulSouth Korea 115 works
  10. 10 New YorkUnited States 112 works

Where it is the local speciality

  1. LuzhouCN · 57.7 works23×
← less than its size predicts1×more →

Location quotient: how much more of its research is in Peptidase Inhibition and Analysis than the world average.

See Peptidase Inhibition and Analysis on the map

Where is the best place to study Peptidase Inhibition and Analysis?

Among universities, judged by research, Harvard University, University of Dundee and Sun Yat-sen University score highest, combining excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.

0%20%40%mean 17.56%fractional works in this field (log) →share of work in the world top 10% →University of DundeeHarvard UniversityPeking UniversitySun Yat-sen University
above the meannear itbelow it

One dot per university in the first ten of the table below, at the default weights. The upper left is the interesting corner: small places doing unusually strong work.

Excellenceshare of its work in the world top 10%, 2022-now and all time averaged
40%
Specialisationhow much of its work is in this field, counted up to 10× the world share
10%
Sizeits output in this field, on a log scale
30%
Growthoutput growth, counted from -20% to +20%
10%
Internationalshare of its work with a co-author abroad
10%
Each slider sets a weight; the share it gets of the score is beside it.
#UniversityScoreTop 10%SpecialisationWorksGrowth
1Harvard UniversityUnited States 77.818.1%3.7×103 +12.1%
2University of DundeeUnited Kingdom 65.337.2%7.2×11 +10.7%
3Sun Yat-sen UniversityChina 63.812.1%5.5×99 +88.7%
4Peking UniversityChina 61.913.0%4.4×79 +56.0%
5Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina 61.713.1%8.5×79 +84.2%
6Sichuan UniversityChina 61.714.8%3.9×77 +82.1%
7China Pharmaceutical UniversityChina 60.722.2%16.3×32 +73.9%
8Shanghai Jiao Tong UniversityChina 60.511.0%3.6×92 +71.6%
9Southern Medical UniversityChina 58.515.2%8.7×47 +114.9%
10Huazhong University of Science and TechnologyChina 58.318.9%3.0×47 +85.5%

Universities only. The score blends excellence (40%), size (30%), specialisation (10%), growth (10%), international reach (10%), 2022-now; growth compares 2018-21 with 2022-25 and counts up to +20%, since a jump from a small base is mostly noise.

Every institution in Peptidase Inhibition and Analysis, country by country

Is Peptidase Inhibition and Analysis research growing?

Output in 2022-2025 was 22% higher than in 2018-2021, peaking in 2025. The fastest-growing topics are Peptidase Inhibition and Analysis.

still counting19801990200020102020
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is Peptidase Inhibition and Analysis as a percentage of every work published that year, 0.045% in 2024.

still counting0.050%0.10%Peptidase Inhibition and Analysis0.044% in 202519801990200020102020

Fractional works of Peptidase Inhibition and Analysis over all fractional works that year. How the balance of science has shifted.

How much of it reaches the world top 10%

Year by year.

still counting5%10%15%Peptidase Inhibition and Analysis10.0% in 2025200020102020

Of each year's works in it, the share that reached the world's 10% most cited for their field and year. A field is the world for its own topics, so there is no other line to hold it against.

Which topics inside it are moving

Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.

Discussion

Ask a question or share a note about Peptidase Inhibition and Analysis. Posts are plain text and can be reported.